Table of Content
"1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.2.2 MARKETS COVERED 37
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION 37
1.2.3 YEARS CONSIDERED FOR THE STUDY 38
1.3 CURRENCY 38
1.4 LIMITATIONS 38
1.5 STAKEHOLDERS 39
1.6 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.2 RESEARCH APPROACH 41
FIGURE 2 CANCER BIOMARKERS MARKET: RESEARCH DESIGN 41
2.2.1 SECONDARY DATA 42
2.2.1.1 Key data from secondary sources 42
2.2.2 PRIMARY DATA 43
2.2.2.1 Primary sources 44
2.2.2.2 Key data from primary sources 44
2.2.2.3 Key industry insights 45
2.2.2.4 Breakdown of primary interviews 46
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND
DEMAND SIDE PARTICIPANTS 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 46
2.3 MARKET SIZE ESTIMATION 47
2.3.1 BOTTOM-UP APPROACH 47
2.3.1.1 Approach 1: Company revenue estimation approach 48
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 48
2.3.1.2 Approach 2: Presentations of companies and primary interviews 48
2.3.1.3 Growth forecast 49
2.3.1.4 CAGR projections 49
FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 49
2.3.2 TOP-DOWN APPROACH 50
FIGURE 7 CANCER BIOMARKERS MARKET: TOP-DOWN APPROACH 50
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 51
FIGURE 8 DATA TRIANGULATION METHODOLOGY 51
2.5 MARKET SHARE 52
2.6 ASSUMPTIONS FOR THE STUDY 52
2.7 LIMITATIONS 53
2.8 RISK ASSESSMENT 53
2.8.1 RISK ASSESSMENT: CANCER BIOMARKERS MARKET 53
2.9 GROWTH RATE ASSUMPTIONS 54
2.10 COVID-19 HEALTH ASSESSMENT 54
2.11 COVID-19 ECONOMIC ASSESSMENT 54
2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO 54
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 55
FIGURE 10 RECOVERY SCENARIO OF GLOBAL ECONOMY 56
2.13 ASSESSMENT OF IMPACT OF COVID-19 ON CANCER BIOMARKERS MARKET 57
3 EXECUTIVE SUMMARY 58
FIGURE 11 CANCER BIOMARKERS MARKET, BY BIOMARKERS TYPE,
2021 VS. 2026 (USD MILLION) 58
FIGURE 12 CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2021 VS. 2026 (USD MILLION) 59
FIGURE 13 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 60
FIGURE 14 CANCER BIOMARKERS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 60
FIGURE 15 CANCER BIOMARKERS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 61
4 PREMIUM INSIGHTS 62
4.1 CANCER BIOMARKERS MARKET OVERVIEW 62
FIGURE 16 RISING TECHNOLOGICAL ADVANCEMENTS FOR THE DEVELOPMENT OF CANCER BIOMARKERS TO DRIVE MARKET GROWTH 62
4.2 CANCER BIOMARKERS MARKET SHARE, BY BIOMARKER TYPE, 2021 VS. 2026 63
FIGURE 17 THE PROTEIN BIOMARKERS SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 63
4.3 CANCER BIOMARKERS MARKET SHARE, BY CANCER TYPE, 2021 VS. 2026 63
FIGURE 18 LUNG CANCER SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 63
4.4 CANCER BIOMARKERS MARKET SHARE, BY PROFILING TECHNOLOGY, 2021 VS. 2026 64
FIGURE 19 THE OMICS TECHNOLOGIES SEGMENT IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 64
4.5 CANCER BIOMARKERS MARKET SHARE, BY APPLICATION, 2021 VS. 2026 64
FIGURE 20 HOSPITALS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 64
4.6 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65
FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE
DURING FORECAST PERIOD 65
5 MARKET OVERVIEW 66
5.1 INTRODUCTION 66
5.2 MARKET DYNAMICS 67
FIGURE 22 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 67
5.2.1 DRIVERS 67
5.2.1.1 Rising technological advancements in the development of cancer biomarkers 67
5.2.1.2 Increasing incidence of cancer worldwide 68
TABLE 1 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS.
2030 VS. 2040 (MILLION) 68
TABLE 2 PROJECTED INCREASE IN THE GLOBAL NUMBER OF CANCER PATIENTS, 2015-2O35 69
5.2.1.3 Increasing use of cancer biomarkers in drug discovery & development 69
5.2.1.4 Increasing R&D on cancer biomarkers 70
5.2.2 RESTRAINTS 70
5.2.2.1 Technical issues related to sample collection and storage 70
5.2.2.2 High capital investments and extensive timelines for the development of cancer biomarkers 71
TABLE 3 TIMEFRAME FOR THE DEVELOPMENT OF BIOMARKERS 71
5.2.2.3 Unfavorable regulatory and reimbursement scenario 71
5.2.3 OPPORTUNITIES 72
5.2.3.1 Increased recognition of personalized medicine 72
FIGURE 23 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS 73
5.2.3.2 Growing application areas of companion diagnostics 73
5.2.3.3 Emerging economies 73
5.2.4 CHALLENGES 74
5.2.4.1 Challenges associated with cancer biomarker validation 74
5.2.4.2 Shortage of skilled professionals 74
5.3 IMPACT OF COVID-19 ON CANCER BIOMARKERS MARKET 75
5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS 77
5.4.1 CANCER BIOMARKERS MARKET 77
FIGURE 24 PESSIMISTIC SCENARIO 77
FIGURE 25 OPTIMISTIC SCENARIO 77
FIGURE 26 REALISTIC SCENARIO 78
5.5 PRICING ANALYSIS 79
TABLE 4 PRICE OF CANCER BIOMARKERS BY PRODUCT & SERVICE (2021) 79
5.6 PATENT ANALYSIS 80
5.6.1 PATENT ANALYSIS OF THE CANCER BIOMARKERS MARKET 80
5.7 TRADE ANALYSIS 81
5.7.1 TRADE ANALYSIS FOR MAGNETIC RESONANCE IMAGING (MRI) SYSTEMS 81
TABLE 5 IMPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016–2020 (USD MILLION) 81
TABLE 6 EXPORT DATA FOR MRI SYSTEMS, BY COUNTRY, 2016–2020 (USD MILLION) 81
5.8 VALUE CHAIN ANALYSIS 82
FIGURE 27 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE 82
5.9 SUPPLY CHAIN ANALYSIS 83
FIGURE 28 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 83
5.10 ECOSYSTEM ANALYSIS OF CANCER BIOMARKERS MARKET 84
FIGURE 29 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 84
5.10.1 ROLE IN ECOSYSTEM 84
5.11 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 7 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.11.1 THREAT OF NEW ENTRANTS 85
5.11.2 THREAT OF SUBSTITUTES: 85
5.11.3 BARGAINING POWER OF BUYERS 85
5.11.4 BARGAINING POWER OF SUPPLIERS 85
5.11.5 DEGREE OF COMPETITION 86
5.12 REGULATORY ANALYSIS 86
5.12.1 INTRODUCTION 86
5.12.2 CANCER BIOMARKERS QUALIFICATION IN THE US 86
5.12.3 CANCER BIOMARKERS QUALIFICATION IN THE EU 86
5.12.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN THE EU AND THE US 87
5.12.5 METHOD: EMA APPROVALS 87
5.12.6 METHOD: FDA APPROVALS 88
5.13 TECHNOLOGY ANALYSIS 88
5.14 PESTLE ANALYSIS 91
5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS 92
5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC 92
FIGURE 30 YC-YCC SHIFT FOR CANCER BIOMARKERS MARKET 92
6 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE 93
6.1 INTRODUCTION 94
TABLE 8 CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 94
TABLE 9 CANCER BIOMARKERS MARKET FOR BIOMARKERS TYPE,
BY REGION, 2020–2026 (USD MILLION) 94
6.2 PROTEIN BIOMARKERS 95
6.2.1 INCREASED EFFORTS OF PHARMACEUTICAL COMPANIES TO DISCOVER PROTEIN BIOMARKERS FOR EARLY STAGES TO DRIVE MARKET GROWTH 95
TABLE 10 CANCER BIOMARKERS MARKET FOR PROTEIN BIOMARKERS, BY REGION, 2020–2026 (USD MILLION) 95
6.3 GENETIC BIOMARKERS 96
6.3.1 ADVANCEMENTS IN HIGH-THROUGHPUT TECHNOLOGIES TO
DRIVE MARKET GROWTH 96
TABLE 11 CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS,
BY TYPE, 2020–2026 (USD MILLION) 96
TABLE 12 CANCER BIOMARKERS MARKET FOR GENETIC BIOMARKERS,
BY REGION, 2020–2026 (USD MILLION) 97
6.3.2 LUNG CANCER 97
6.3.3 BREAST CANCER 99
6.3.4 PROSTATE CANCER 99
6.3.5 LEUKEMIA 100
6.3.6 OTHER CANCERS 101
6.4 OTHER CANCER BIOMARKERS 102
TABLE 13 CANCER BIOMARKERS MARKET FOR OTHER CANCER BIOMARKERS,
BY REGION, 2020–2026 (USD MILLION) 102
7 CANCER BIOMARKERS MARKET, BY CANCER TYPE 103
7.1 INTRODUCTION 104
TABLE 14 CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 104
TABLE 15 CANCER BIOMARKERS MARKET FOR CANCER TYPE, BY REGION,
2020–2026 (USD MILLION) 105
7.2 BREAST CANCER 105
7.2.1 AVAILABILITY & UTILISATION OF ADVANCED TECHNOLOGIES BY MAJOR PLAYERS IN BREAST CANCER DETECTION TO DRIVE MARKET GROWTH 105
TABLE 16 BREAST CANCER INCIDENCE, BY REGION, 2020 VS 2040 106
TABLE 17 CANCER BIOMARKERS MARKET FOR BREAST CANCER, BY REGION,
2020–2026 (USD MILLION) 106
7.3 LUNG CANCER 106
7.3.1 INCREASING FOCUS ON LUNG CANCER BIOMARKERS DEVELOPMENT TO DRIVE MARKET GROWTH 106
TABLE 18 LUNG CANCER INCIDENCE, BY REGION, 2020 VS 2040 107
TABLE 19 CANCER BIOMARKERS MARKET FOR LUNG CANCER, BY REGION,
2020–2026 (USD MILLION) 107
7.4 COLORECTAL CANCER (CRC) 108
7.4.1 RISING DEMAND FOR BIOMARKERS IN THE EARLY DIAGNOSIS &
PROGNOSIS OF CRC TO DRIVE THE MARKET GROWTH 108
TABLE 20 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS 2040 108
TABLE 21 CANCER BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2026 (USD MILLION) 108
7.5 PROSTATE CANCER 109
7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES ARE ENABLING THE DEVELOPMENT OF NEW BIOMARKERS FOR PROSTATE CANCER 109
TABLE 22 CANCER BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2020–2026 (USD MILLION) 109
7.6 MELANOMA 110
7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE THE MARKET GROWTH 110
TABLE 23 MELANOMA INCIDENCE, BY REGION, 2020 VS 2040 110
TABLE 24 CANCER BIOMARKERS MARKET FOR MELANOMA, BY REGION,
2020–2026 (USD MILLION) 111
7.7 LEUKEMIA 111
7.7.1 RESEARCH STUDIES FOR THE DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS IN LEUKEMIA TO DRIVE MARKET GROWTH 111
TABLE 25 CANCER BIOMARKERS MARKET FOR LEUKEMIA, BY REGION,
2020–2026 (USD MILLION) 112
7.8 THYROID CANCER 112
7.8.1 RESEARCH UNDERTAKEN FOR THE IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO DRIVE THE MARKET GROWTH 112
TABLE 26 CANCER BIOMARKERS MARKET FOR THYROID CANCER, BY REGION,
2020–2026 (USD MILLION) 113
7.9 BLADDER CANCER 113
7.9.1 APPROVAL OF SEVERAL URINARY BIOMARKERS FOR THE DETECTION OF BLADDER CANCER TO SUPPORT THE SEGMENT GROWTH 113
TABLE 27 CANCER BIOMARKERS MARKET FOR BLADDER CANCER, BY REGION,
2020–2026 (USD MILLION) 114
7.10 NON-HODGKIN’S LYMPHOMA (NHL) 114
7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE THE MARKET GROWTH 114
TABLE 28 CANCER BIOMARKERS MARKET FOR NON-HODGKIN’S LYMPHOMA,
BY REGION, 2020–2026 (USD MILLION) 115
7.11 KIDNEY CANCER 115
7.11.1 DEVELOPMENT OF SEVERAL NEW TARGETED THERAPIES FOR THE TREATMENT OF KIDNEY CANCER TO DRIVE THE MARKET GROWTH 115
TABLE 29 CANCER BIOMARKERS MARKET FOR KIDNEY CANCER, BY REGION,
2020–2026 (USD MILLION) 116
7.12 OTHER CANCERS 116
TABLE 30 CANCER BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION,
2020–2026 (USD MILLION) 117
8 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY 118
8.1 INTRODUCTION 119
TABLE 31 CANCER BIOMARKERS MARKET FOR PROFILING TECHNOLOGY, BY TYPE, 2020–2026 (USD MILLION) 119
TABLE 32 CANCER BIOMARKERS MARKET FOR PROFILING TECHNOLOGY, BY REGION, 2020–2026 (USD MILLION) 119
8.2 OMICS TECHNOLOGY 120
8.2.1 INCREASING DEMAND FOR ADVANCED OMICS TECHNOLOGIES TO DRIVE MARKET GROWTH 120
TABLE 33 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGY, BY TYPE,
2020–2026 (USD MILLION) 120
TABLE 34 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGY, BY REGION, 2020–2026 (USD MILLION) 121
8.2.2 PROTEOMICS 121
8.2.2.1 Increasing discovery rate of protein biomarkers and the rising need for rapid and cost-efficient diagnostic tests to drive segment growth 121
TABLE 35 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION,
2020–2026 (USD MILLION) 122
8.2.3 GENOMICS 122
8.2.3.1 The rising potential of genomics technologies in the development of biomarkers for disease prediction 122
TABLE 36 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE,
2020–2026 (USD MILLION) 123
TABLE 37 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION,
2020–2026 (USD MILLION) 123
8.2.3.2 NEXT-GENERATION SEQUENCING (NGS) 124
8.2.3.2.1 Introducing advanced NGS platforms by leading players to increase productivity to drive the growth of this segment 124
TABLE 38 CANCER BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING,
BY REGION, 2020–2026 (USD MILLION) 124
8.2.3.3 POLYMERASE CHAIN REACTION (PCR) 125
8.2.3.3.1 Cost-effectiveness and the easy availability of PCR tests to propel the growth of this segment 125
TABLE 39 CANCER BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2020–2026 (USD MILLION) 126
8.2.4 OTHER OMICS TECHNOLOGIES 126
TABLE 40 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES,
BY REGION, 2020–2026 (USD MILLION) 127
8.3 IMAGING TECHNOLOGIES 127
8.3.1 THE USE OF IMAGING BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT PROCESSES TO DRIVE THE GROWTH OF THIS MARKET 127
TABLE 41 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2020–2026 (USD MILLION) 128
TABLE 42 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2020–2026 (USD MILLION) 128
8.3.2 ULTRASOUND IMAGING 128
8.3.2.1 Use of ultrasound for biomarker research in the understanding of disease onset & progression to drive the growth of this segment 128
TABLE 43 CANCER BIOMARKERS MARKET FOR ULTRASOUND IMAGING, BY REGION, 2020–2026 (USD MILLION) 129
8.3.3 COMPUTED TOMOGRAPHY (CT) 129
8.3.3.1 The adoption of CT in cancer biomarker discovery is
increasing rapidly 129
TABLE 44 CANCER BIOMARKERS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2020–2026 (USD MILLION) 130
8.3.4 MAGNETIC RESONANCE IMAGING (MRI) 130
8.3.4.1 MRI use in differentiating normal and diseased tissues to pinpoint cancerous cells precisely supports the growth of this segment 130
TABLE 45 CANCER BIOMARKERS MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 2020–2026 (USD MILLION) 131
8.3.5 POSITRON EMISSION TOMOGRAPHY (PET) 131
8.3.5.1 Development of lab-on-chip-based multiplex assays to support the market growth 131
TABLE 46 CANCER BIOMARKERS MARKET FOR POSITRON EMISSION TOMOGRAPHY,
BY REGION, 2020–2026 (USD MILLION) 132
8.3.6 MAMMOGRAPHY 132
8.3.6.1 Advanced technologies like 3D mammography to drive the growth of this segment 132
TABLE 47 CANCER BIOMARKERS MARKET FOR MAMMOGRAPHY, BY REGION,
2020–2026 (USD MILLION) 133
8.4 IMMUNOASSAYS 133
8.4.1 THE INCREASING PREVALENCE OF BREAST CANCER IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT 133
TABLE 48 CANCER BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION,
2020–2026 (USD MILLION) 135
8.5 BIOINFORMATICS 135
8.5.1 RISING TECHNOLOGICAL ADVANCEMENTS AND THE GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET GROWTH 135
TABLE 49 CANCER BIOMARKERS MARKET FOR BIOINFORMATICS, BY REGION,
2020–2026 (USD MILLION) 136
8.6 CYTOGENETICS 136
8.6.1 CYTOGENETICS ARE GENETICS-BASED TESTS THAT ARE RELIABLE IN THE QUANTITATIVE & QUALITATIVE EVALUATION OF BIOMARKERS 136
TABLE 50 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY TYPE,
2020–2026 A(USD MILLION) 137
TABLE 51 CANCER BIOMARKERS MARKET FOR CYTOGENETICS, BY REGION,
2020–2026 (USD MILLION) 137
8.6.2 IN-SITU HYBRIDIZATION (ISH) 137
8.6.2.1 Use of ISH-based diagnostic tests help identify specific biomarkers in clinical trials 137
TABLE 52 CANCER BIOMARKERS MARKET FOR IN-SITU HYBRIDIZATION, BY REGION, 2020–2026 (USD MILLION) 138
8.6.3 OTHER CYTOGENETICS-BASED TESTS 138
TABLE 53 CANCER BIOMARKERS MARKET FOR OTHER CYTOGENETICS-BASED TESTS, BY REGION, 2020–2026 (USD MILLION) 139
9 CANCER BIOMARKERS MARKET, BY APPLICATION 140
9.1 INTRODUCTION 141
TABLE 54 CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 141
TABLE 55 CANCER BIOMARKERS MARKET FOR APPLICATION, BY REGION,
2020–2026 (USD MILLION) 141
9.2 DIAGNOSTICS 142
9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO DRIVE MARKET GROWTH 142
TABLE 56 CANCER BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION,
2020–2026 (USD MILLION) 142
9.3 RESEARCH & DEVELOPMENT 143
9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON BIOMARKERS USE IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET GROWTH 143
TABLE 57 CANCER BIOMARKERS MARKET FOR RESEARCH & DEVELOPMENT,
BY REGION, 2020–2026 (USD MILLION) 143
9.4 PROGNOSTICS 144
9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO DRIVE MARKET GROWTH 144
TABLE 58 CANCER BIOMARKERS MARKET FOR PROGNOSTICS, BY REGION,
2020–2026 (USD MILLION) 144
9.5 RISK ASSESSMENT 144
9.5.1 RISK ASSESSMENT BIOMARKERS TO INCREASE CANCER CLINICAL TRIALS FOR DRUG DEVELOPMENT 144
TABLE 59 CANCER BIOMARKERS MARKET FOR RISK ASSESSMENT, BY REGION,
2020–2026 (USD MILLION) 145
9.6 OTHER APPLICATIONS 145
TABLE 60 CANCER BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2026 (USD MILLION) 146
10 CANCER BIOMARKERS MARKET, BY REGION 147
10.1 INTRODUCTION 148
TABLE 61 CANCER BIOMARKERS MARKET, BY REGION, 2020–2026 (USD MILLION) 148
10.2 NORTH AMERICA 149
TABLE 62 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020,
BY CANCER TYPE 149
FIGURE 31 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 150
FIGURE 32 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT 150
TABLE 63 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 151
TABLE 64 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 151
TABLE 65 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE, 2020–2026 (USD MILLION) 152
TABLE 66 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 152
TABLE 67 NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 152
TABLE 68 NORTH AMERICA: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 153
TABLE 69 NORTH AMERICA: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 153
TABLE 70 NORTH AMERICA: CYTOGENETICS MARKET, BY TYPE,
2020–2026 (USD MILLION) 153
TABLE 71 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 154
10.2.1.1 Increasing use of cancer biomarkers for cancer treatment drives the market growth 154
TABLE 72 KEY GROWTH STRATEGIES BY LEADING PLAYER FOR THE DEVELOPMENT
OF CANCER BIOMARKERS 155
TABLE 73 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 156
TABLE 74 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 156
TABLE 75 US: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 157
TABLE 76 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 157
TABLE 77 US: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 157
TABLE 78 US: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 158
TABLE 79 US: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 158
TABLE 80 US: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 158
TABLE 81 US: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 159
10.2.2 CANADA 159
10.2.2.1 Increasing government initiatives for the discovery & development of cancer biomarkers to drive the market growth 159
TABLE 82 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 160
TABLE 83 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 161
TABLE 84 CANADA: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 161
TABLE 85 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 162
TABLE 86 CANADA: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 162
TABLE 87 CANADA: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 162
TABLE 88 CANADA: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 163
TABLE 89 CANADA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 163
TABLE 90 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 163
10.3 EUROPE 164
FIGURE 33 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 165
TABLE 91 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 165
TABLE 92 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 166
TABLE 93 EUROPE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 166
TABLE 94 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY , 2020–2026 (USD MILLION) 167
TABLE 95 EUROPE: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 167
TABLE 96 EUROPE: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 167
TABLE 97 EUROPE: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 168
TABLE 98 EUROPE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 168
TABLE 99 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 168
10.3.1 GERMANY 169
10.3.1.1 Favorable government health policies to drive the market growth for cancer biomarkers in Germany 169
TABLE 100 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 169
TABLE 101 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 170
TABLE 102 GERMANY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 170
TABLE 103 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 171
TABLE 104 GERMANY: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 171
TABLE 105 GERMANY: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 171
TABLE 106 GERMANY: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 172
TABLE 107 GERMANY: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 172
TABLE 108 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 172
10.3.2 UK 173
10.3.2.1 Availability of government funding and strategic collaborations with biotech firms have significantly boosted the adoption of biomarkers in the UK 173
TABLE 109 UK: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 173
TABLE 110 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 174
TABLE 111 UK: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 174
TABLE 112 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY ,
2020–2026 (USD MILLION) 175
TABLE 113 UK: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 175
TABLE 114 UK: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 175
TABLE 115 UK: IMAGING TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 176
TABLE 116 UK: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 176
TABLE 117 UK: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 176
10.3.3 FRANCE 177
10.3.3.1 Increasing government investments in genomics & proteomics research to drive the market growth in France 177
TABLE 118 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 177
TABLE 119 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 178
TABLE 120 FRANCE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 178
TABLE 121 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 179
TABLE 122 FRANCE: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 179
TABLE 123 FRANCE: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 179
TABLE 124 FRANCE: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 180
TABLE 125 FRANCE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 180
TABLE 126 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 180
10.3.4 ITALY 181
10.3.4.1 Increasing research activities on the discovery for novel cancer biomarkers using tissue diagnostic techniques to drive the market growth 181
TABLE 127 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 182
TABLE 128 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 182
TABLE 129 ITALY: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 183
TABLE 130 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 183
TABLE 131 ITALY: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 183
TABLE 132 ITALY: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 184
TABLE 133 ITALY: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 184
TABLE 134 ITALY: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 184
TABLE 135 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 185
10.3.5 SPAIN 185
10.3.5.1 Increasing focus on personalized medicine to drive the market growth for cancer biomarkers in Spain 185
TABLE 136 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 186
TABLE 137 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 186
TABLE 138 SPAIN: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 187
TABLE 139 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 187
TABLE 140 SPAIN: OMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 187
TABLE 141 SPAIN: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 188
TABLE 142 SPAIN: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 188
TABLE 143 SPAIN: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 188
TABLE 144 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 189
10.3.6 REST OF EUROPE 189
TABLE 145 ROE: CANCER BIOMARKERS MARKET, BY CANCER TYPE,
2020–2026 (USD MILLION) 190
TABLE 146 ROE: CANCER BIOMARKERS MARKET, BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 190
TABLE 147 ROE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 191
TABLE 148 ROE: OMICS TECHNOLOGIES MARKET, BY TYPE, 2020–2026 (USD MILLION) 191
TABLE 149 ROE: GENOMICS TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 191
TABLE 150 ROE: IMAGING TECHNOLOGIES MARKET, BY TYPE,
2020–2026 (USD MILLION) 192
TABLE 151 ROE: CYTOGENETICS MARKET, BY TYPE, 2020–2026 (USD MILLION) 192
TABLE 152 ROE: CANCER BIOMARKERS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 192
FIGURE 34 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 193
FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT 194
TABLE 153 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY COUNTRY,
2020–2026 (USD MILLION) 195
TABLE 154 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 195
TABLE 155 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 196
TABLE 156 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 196
TABLE 157 ASIA PACIFIC: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 196
TABLE 158 ASIA PACIFIC: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 197
TABLE 159 ASIA PACIFIC: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 197
TABLE 160 ASIA PACIFIC: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 197
TABLE 161 ASIA PACIFIC: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 198
10.3.7 CHINA 198
10.3.7.1 Increasing burden of diseases and growing focus on novel drugs development to drive demand for cancer biomarkers 198
TABLE 162 CHINA: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040 199
TABLE 163 CHINA: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 199
TABLE 164 CHINA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 200
TABLE 165 CHINA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 200
TABLE 166 CHINA: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 200
TABLE 167 CHINA: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 201
TABLE 168 CHINA: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 201
TABLE 169 CHINA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 201
TABLE 170 CHINA: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 202
10.3.8 JAPAN 202
10.3.8.1 Strategic collaborations with leading pharmaceutical companies to drive market growth 202
TABLE 171 JAPAN: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040 203
TABLE 172 JAPAN: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 204
TABLE 173 JAPAN: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 204
TABLE 174 JAPAN: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 205
TABLE 175 JAPAN: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 205
TABLE 176 JAPAN: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 205
TABLE 177 JAPAN: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 206
TABLE 178 JAPAN: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 206
TABLE 179 JAPAN: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 206
10.3.9 INDIA 207
10.3.9.1 Increased demand for early cancer diagnosis to support market growth 207
TABLE 180 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 208
TABLE 181 INDIA: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 208
TABLE 182 INDIA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 209
TABLE 183 INDIA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY,
2020–2026 (USD MILLION) 209
TABLE 184 INDIA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION) 209
TABLE 185 INDIA: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 210
TABLE 186 INDIA: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 210
TABLE 187 INDIA: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 210
TABLE 188 INDIA: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 211
10.3.10 REST OF ASIA PACIFIC 211
TABLE 189 ROAPAC: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 212
TABLE 190 ROAPAC: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE,
2020–2026 (USD MILLION) 212
TABLE 191 ROAPAC: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 213
TABLE 192 ROAPAC: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 213
TABLE 193 ROAPAC: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 213
TABLE 194 ROAPAC: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 214
TABLE 195 ROAPAC: CYTOGENETICS MARKET BY TYPE, 2020–2026 (USD MILLION) 214
TABLE 196 ROAPAC: CANCER BIOMARKERS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 214
10.4 LATIN AMERICA 215
10.4.1 GROWING CANCER RESEARCH AND MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH 215
TABLE 197 LATIN AMERICA: CANCER INCIDENCE BY TYPE OF CANCER, 2020 VS. 2040 215
TABLE 198 LATIN AMERICA: CANCER BIOMARKERS MARKET BY CANCER TYPE,
2020–2026 (USD MILLION) 216
TABLE 199 LATIN AMERICA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION) 216
TABLE 200 LATIN AMERICA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 217
TABLE 201 LATIN AMERICA: OMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION) 217
TABLE 202 LATIN AMERICA: GENOMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 217
TABLE 203 LATIN AMERICA: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 218
TABLE 204 LATIN AMERICA: CYTOGENETICS MARKET BY TYPE,
2020–2026 (USD MILLION) 218
TABLE 205 LATIN AMERICA: CYTOGENETICS MARKET BY APPLICATION,
2020–2026 (USD MILLION) 218
10.5 MIDDLE EAST & AFRICA 219
10.5.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH 219
TABLE 206 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY CANCER TYPE, 2020–2026 (USD MILLION) 220
TABLE 207 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY BIOMARKER TYPE, 2020–2026 (USD MILLION) 220
TABLE 208 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY PROFILING TECHNOLOGY, 2020–2026 (USD MILLION) 221
TABLE 209 MIDDLE EAST & AFRICA: OMICS TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 221
TABLE 210 MIDDLE EAST & AFRICA: GENOMICS TECHNOLOGIES MARKET BY TYPE, 2020–2026 (USD MILLION) 221
TABLE 211 MIDDLE EAST & AFRICA: IMAGING TECHNOLOGIES MARKET BY TYPE,
2020–2026 (USD MILLION) 222
TABLE 212 MIDDLE EAST & AFRICA: CYTOGENETICS MARKET BY TYPE,
2020–2026 (USD MILLION) 222
TABLE 213 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET BY APPLICATION, 2020–2026 (USD MILLION) 222
11 COMPETITIVE LANDSCAPE 223
11.1 OVERVIEW 223
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 223
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE CANCER BIOMARKERS MARKET 224
TABLE 214 STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES 224
11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 225
FIGURE 36 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CANCER BIOMARKERS MARKET 225
11.4 MARKET SHARE ANALYSIS 226
TABLE 215 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION 226
11.5 COMPANY EVALUATION QUADRANT 227
11.5.1 STARS 227
11.5.2 EMERGING LEADERS 227
11.5.3 PERVASIVE PLAYERS 227
11.5.4 PARTICIPANTS 228
FIGURE 38 CANCER BIOMARKERS MARKET: COMPANY EVALUATION QUADRANT, 2020 228
11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020) 229
11.6.1 PROGRESSIVE COMPANIES 229
11.6.2 STARTING BLOCKS 229
11.6.3 RESPONSIVE COMPANIES 229
11.6.4 DYNAMIC COMPANIES 229
FIGURE 39 CANCER BIOMARKERS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2020 230
11.7 COMPETITIVE BENCHMARKING 230
FIGURE 40 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CANCER BIOMARKERS MARKET 230
TABLE 216 COMPANY PRODUCT FOOTPRINT 231
TABLE 217 COMPANY REGIONAL FOOTPRINT 231
11.8 COMPETITIVE SCENARIO 232
11.8.1 PRODUCT LAUNCHES & APPROVALS 232
TABLE 218 KEY PRODUCT LAUNCHES & APPROVALS 232
11.8.2 DEALS 233
TABLE 219 DEALS 233"
"12 COMPANY PROFILES 234
12.1 KEY PLAYERS 234
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 F. HOFFMANN-LA ROCHE LTD. 234
TABLE 220 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 234
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 235
12.1.2 THERMO FISHER SCIENTIFIC INC. 238
TABLE 221 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 238
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020) 239
12.1.3 QIAGEN N.V. 244
TABLE 222 QIAGEN N.V.: BUSINESS OVERVIEW 244
FIGURE 43 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 245
12.1.4 ILLUMINA, INC. 250
TABLE 223 ILLUMINA, INC.: BUSINESS OVERVIEW 250
FIGURE 44 ILLUMINA, INC.: COMPANY SNAPSHOT 251
12.1.5 BIO-RAD LABORATORIES, INC. 254
TABLE 224 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 254
FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 255
12.1.6 ABBOTT LABORATORIES 257
TABLE 225 ABBOTT LABORATORIES: BUSINESS OVERVIEW 257
FIGURE 46 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 258
12.1.7 BIOMÉRIEUX SA 260
TABLE 226 BIOMÉRIEUX SA: BUSINESS OVERVIEW 260
FIGURE 47 BIOMÉRIEUX SA: COMPANY SNAPSHOT 261
12.1.8 BECTON DICKINSON AND COMPANY 262
TABLE 227 BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW 262
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 263
12.1.9 MERCK MILLIPORE 265
TABLE 228 MERCK MILLIPORE: BUSINESS OVERVIEW 265
FIGURE 49 MERCK MILLIPORE: COMPANY SNAPSHOT 266
12.1.10 AGILENT TECHNOLOGIES 268
TABLE 229 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW 268
FIGURE 50 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021) 269
12.2 OTHER PLAYERS 271
12.2.1 MYRIAD GENETICS, INC. 271
12.2.2 SYSMEX CORPORATION 272
12.2.3 HOLOGIC, INC. 273
12.2.4 QUEST DIAGNOSTICS 273
12.2.5 CENTOGENE N.V. 274
12.2.6 PERKINELMER, INC. 274
12.2.7 SIEMENS HEALTHINEERS 275
12.2.8 EXACT SCIENCES 275
12.2.9 R&D SYSTEMS, INC. 276
12.2.10 BIOVISION INC. 277
12.2.11 OLINK 277
12.2.12 ASURAGEN, INC. 278
12.2.13 MESO SCALE DIAGNOSTICS, LLC 278
12.2.14 INVIVOSCRIBE, INC. 279
12.2.15 SEEGENE TECHNOLOGIES, INC. 279
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 280
13.1 DISCUSSION GUIDE 280
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 284
13.3 AVAILABLE CUSTOMIZATIONS 286
13.4 RELATED REPORTS 286
13.5 AUTHOR DETAILS 287"
US $
Euro €
GBP £